| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0987ba7c1b1ce300b1f141c5a1fc673f |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-14 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 |
| filingDate |
2020-11-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e3073b8f1970ffde47d4d9e0b3dc13c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a61a1dc4bce82bcfc412b5b6641ca6d5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a193aa172d7c624fbd218a9608fd5140 |
| publicationDate |
2020-12-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20200135922-A |
| titleOfInvention |
A sustained-release lipid pre-concentrate and a sustained-release injectable pharmaceutical composition in the form of lipid solution comprising the same |
| abstract |
The present invention has 14 to 20 carbon atoms (C 14 to C 20 ) unsaturated fatty acids; Phospholipids; And a sustained-release lipid precursor formulation in the form of a lipid solution comprising α-tocopherol acetate, which does not contain diacyl glycerol and sorbitan unsaturated fatty acid ester; A precursor formulation that forms liquid crystals in an aqueous medium is provided. In addition, the present invention provides a pharmaceutical composition for sustained-release injection in the form of a lipid solution containing the precursor and a pharmacologically active substance, which does not contain diacyl glycerol and sorbitan unsaturated fatty acid ester. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022270956-A1 |
| priorityDate |
2019-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |